tbuckley/cabot-search huggingface dataset:
Socioeconomic Determinants of Health and Cardiovascular Outcomes in Women
Authors: Kathryn J Lindley, Niti R Aggarwal, Joan E Briller, Melinda B Davis, Paul Douglass, Kelly C Epps, Jerome L Fleg, Sharonne Hayes, Dipti Itchhaporia, Zainab Mahmoud, Glaucia Maria Moraes De Oliveira, Modele O Ogunniyi, Odayme Quesada, Andrea M Russo, Jyoti Sharma, Malissa J Wood
Journal: Journal of the American College of Cardiology (2021)

Socioeconomic disparities in cardiovascular risk factors and outcomes exist among women, particularly those of minority racial or ethnic backgrounds. Barriers to optimal cardiovascular health begin early in life—with inadequate access to effective contraception, postpartum follow-up, and maternity leave—and result in excess rates of myocardial infarction, stroke, and cardiovascular death in at-risk populations. Contributing factors include reduced access to care, low levels of income and social support, and lack of diversity among cardiology clinicians and within clinical trials. These barriers can be mitigated by optimizing care access via policy change and improving physical access to care in women with geographic or transportation limitations. Addressing structural racism through policy change and bolstering structured community support systems will be key to reducing adverse cardiovascular outcomes among women of racial and ethnic minorities. Diversification of the cardiology workforce to more closely represent the patients we serve will be beneficial to all women.
Preclinical Evaluation of Prgn-3007, a Non-Viral, Multigenic, Autologous ROR1 Ultracar-T ® Therapy with Novel Mechanism of Intrinsic PD-1 Blockade for Treatment of Hematological and Solid Cancers
Authors: Tim Chan, Sean P Scott, Mengyan Du, Cheryl Bolinger, Carol Poortman, Lindsey Shepard, Byron Koenitzer, Adeline Govekung, Carlos Sailor, Rahim Johnson, Jacques Plummer, Steven Zilko, Shourik Dutta, Kannan Kunchithapautham, Taranjit Athwal, Bernward Klocke, Christian Zinser, Maha Abdeladhim, Shamim Ahmad, Simon Metenou, Roshanak Semnani, Douglas E Brough, Rutul R Shah, Helen Sabzevari
Journal: Blood (2021)
Endoscopic ultrasonography in the diagnosis of pathology of the gastrointestinal tract
Authors: Yu.M. Stepanov, N.V. Prolom, I.S. Konenko, S.O. Tarabarov, N.V. Nedzvetskaya
Journal: GASTROENTEROLOGY (2021)

Endoscopic ultrasonography is a relatively new endoscopic method of examination to determine the invasion of tumors of the gastrointestinal tract, detection and sizing of pancreatic tumors, diagnosis of chronic pancreatitis, pathology of the biliary tract. The method combines the possibilities of two studies: endoscopic and ultrasound. The study is performed using a video endoscope, at the end of which is a scanning ultrasound sensor. The advantages of endoscopic ultrasound over traditional ultrasound examination through the anterior abdominal wall are that the ultrasound sensor under visual control through the lumen of the digestive tract can be carried out directly to the investigated object. The use of very high frequencies of ultrasound provides high image quality with a resolution of less than 1 mm, inaccessible to other research methods (ultrasound, computer tomography and magnetic resonance imaging, endoscopic cholangiopancreatography).
Abstract 14971: Association Between Body Mass Index and Atrial Conduction Indices on Surface and Intracardiac Electrocardiogram in Patients With Supraventricular Arrhythmias
Authors: Hatem Al Kassem, Amrish Deshmukh, Zaid Aziz, Stephanie A. Besser, Cevher Ozcan
Journal: Circulation (2019)

Introduction: Obesity is a modifiable risk factor for atrial fibrillation (AF). However, the mechanism by which obesity facilitates AF remains unclear. Hypothesis: High body mass index (BMI) increa...
Catastrophic antiphospholipid syndrome (Asherson’s syndrome) caused by a suspected intestinal neuroendocrine tumor: a case report
Authors: V.P. Shypulіn, V.V. Cherniavskyi, L.S. Hvozdecka, A.V. Neverovskyi, V.V. Tishchenko
Journal: GASTROENTEROLOGY (2021)

Background. Every year, the number of people with rare forms of the disease is increasing worldwide. One of these is the catastrophic antiphospholipid syndrome — Asherson’s syndrome. To date, it is being actively studied, but the pathophysiological mechanisms of its development have not yet been fully investigated. Our work is the first attempt to describe Asherson’s syndrome on the example of a clinical case in Ukraine. Objective: to determine the factors and mechanisms that led to the death of a patient with Asherson’s syndrome in Ukraine. Materials and methods. The structural-logical analysis and the clinical-statistical method were used. Results. Based on clinical and laboratory criteria, our medical team established a clinical diagnosis of systemic lupus erythematosus complicated by a catastrophic antiphospholipid syndrome (CAPS). Despite treatment with glucocorticoids and anticoagulants according to international guidelines, the patient died. The autopsy results showed that the immediate cause of death was a large blood clot that blocked the pulmonary artery and its main branches. Histological examination revealed thrombosis of small vessels of the kidneys and brain; a neuroendocrine tumor (G2; pT3pNxpM1b) of the small intestine with metastases to the liver, brain, myocardium and kidneys was suspected. An additional immunohistochemical study was performed to clarify the histological diagnosis. The morphological picture and results of immunohistochemical study mostly correspond to the moderately differentiated (G2) non-keratinizing squamous cell carcinoma (ICD-O code: 8070/3) with damage to the walls of the small intestine, liver, lungs, kidneys, myocardium and brain. Conclusions. These data emphasize that despite the rarity of Asherson’s syndrome, it is always necessary to consider its probability in the presence of signs of multiple thrombosis and multiple organ failure. Because its development is the result of serious diseases, including connective tissue diseases, malignancies, infections, the etiotropic and pathogenetic treatment can prevent the development of CAPS and death.
Modeling Metastatic Colonization in a Decellularized Organ Scaffold‐Based Perfusion Bioreactor
Authors: Maria Rafaeva, Edward R. Horton, Adina R.D. Jensen, Chris D. Madsen, Raphael Reuten, Oliver Willacy, Christian B. Brøchner, Thomas H. Jensen, Kamilla Westarp Zornhagen, Marina Crespo, Dina S. Grønseth, Sebastian R. Nielsen, Manja Idorn, Per thor Straten, Kristoffer Rohrberg, Iben Spanggaard, Martin Højgaard, Ulrik Lassen, Janine T. Erler, Alejandro E. Mayorca‐Guiliani
Journal: Advanced Healthcare Materials (2021)

Metastatic cancer spread is responsible for most cancer-related deaths. To colonize a new organ, invading cells adapt to, and remodel, the local extracellular matrix (ECM), a network of proteins and proteoglycans underpinning all tissues, and a critical regulator of homeostasis and disease. However, there is a major lack in tools to study cancer cell behavior within native 3D ECM. Here, an in-house designed bioreactor, where mouse organ ECM scaffolds are perfused and populated with cells that are challenged to colonize it, is presented. Using a specialized bioreactor chamber, it is possible to monitor cell behavior microscopically (e.g., proliferation, migration) within the organ scaffold. Cancer cells in this system recapitulate cell signaling observed in vivo and remodel complex native ECM. Moreover, the bioreactors are compatible with co-culturing cell types of different genetic origin comprising the normal and tumor microenvironment. This degree of experimental flexibility in an organ-specific and 3D context, opens new possibilities to study cell-cell and cell-ECM interplay and to model diseases in a controllable organ-specific system ex vivo.
An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci
Authors: Edward Mountjoy, Ellen M. Schmidt, Miguel Carmona, Jeremy Schwartzentruber, Gareth Peat, Alfredo Miranda, Luca Fumis, James Hayhurst, Annalisa Buniello, Mohd Anisul Karim, Daniel Wright, Andrew Hercules, Eliseo Papa, Eric B. Fauman, Jeffrey C. Barrett, John A. Todd, David Ochoa, Ian Dunham, Maya Ghoussaini
Journal: Nature Genetics (2021)
TCT-421 Simple Percutaneous Transaxillary Approach for Transcatheter Aortic Valve Replacement or Impella Pump Implantation
Authors: Jerzy Sacha, Krzysztof Krawczyk, Witold Gwozdz, Jaroslaw Bugajski, Tadeusz Perkowski, Mariusz Darmetko, Robert Kiwus, Radoslaw Gawronski, Piotr Feusette, Wojciech Milejski, Marek Gierlotka, Marek Cisowski
Journal: Journal of the American College of Cardiology (2021)
TCT-369 Durability of Reduced Office-Measured Blood Pressure and Antihypertensive Medication Use After Ultrasound Renal Denervation: 24-Month Results From the RADIANCE-HTN SOLO Trial
Authors: Florian Rader, Ajay Kirtane, Yale Wang, Joost Daemen, Phillip Lurz, Jeremy Sayer, Manish Saxena, Terry Levy, Michel Azizi, Michael Weber
Journal: Journal of the American College of Cardiology (2021)
Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease
Authors: Rajiv Agarwal, Arjun D. Sinha, Andrew E. Cramer, Mary Balmes-Fenwick, Jazmyn H. Dickinson, Fangqian Ouyang, Wanzhu Tu
Journal: New England Journal of Medicine (2021)

Little evidence has been available to support the use of thiazide diuretics to treat hypertension in patients with advanced chronic kidney disease.We randomly assigned patients with stage 4 chronic kidney disease and poorly controlled hypertension, as confirmed by 24-hour ambulatory blood-pressure monitoring, in a 1:1 ratio to receive chlorthalidone at an initial dose of 12.5 mg per day, with increases every 4 weeks if needed to a maximum dose of 50 mg per day, or placebo; randomization was stratified according to previous use of loop diuretics. The primary outcome was the change in 24-hour ambulatory systolic blood pressure from baseline to 12 weeks. Secondary outcomes were the change from baseline to 12 weeks in the urinary albumin-to-creatinine ratio, N-terminal pro-B-type natriuretic peptide level, plasma renin and aldosterone levels, and total body volume. Safety was also assessed.A total of 160 patients underwent randomization, of whom 121 (76%) had diabetes mellitus and 96 (60%) were receiving loop diuretics. At baseline, the mean (±SD) estimated glomerular filtration rate was 23.2±4.2 ml per minute per 1.73 m2 of body-surface area and the mean number of antihypertensive medications prescribed was 3.4±1.4. At randomization, the mean 24-hour ambulatory systolic blood pressure was 142.6±8.1 mm Hg in the chlorthalidone group and 140.1±8.1 mm Hg in the placebo group and the mean 24-hour ambulatory diastolic blood pressure was 74.6±10.1 mm Hg and 72.8±9.3 mm Hg, respectively. The adjusted change in 24-hour systolic blood pressure from baseline to 12 weeks was -11.0 mm Hg (95% confidence interval [CI], -13.9 to -8.1) in the chlorthalidone group and -0.5 mm Hg (95% CI, -3.5 to 2.5) in the placebo group. The between-group difference was -10.5 mm Hg (95% CI, -14.6 to -6.4) (P<0.001). The percent change in the urinary albumin-to-creatinine ratio from baseline to 12 weeks was lower in the chlorthalidone group than in the placebo group by 50 percentage points (95% CI, 37 to 60). Hypokalemia, reversible increases in serum creatinine level, hyperglycemia, dizziness, and hyperuricemia occurred more frequently in the chlorthalidone group than in the placebo group.Among patients with advanced chronic kidney disease and poorly controlled hypertension, chlorthalidone therapy improved blood-pressure control at 12 weeks as compared with placebo. (Funded by the National Heart, Lung, and Blood Institute and the Indiana Institute of Medical Research; CLICK ClinicalTrials.gov number, NCT02841280.).
TCT-152 Clinical and Prognostic Impact From Objective Analysis of Post-Angioplasty Fractional Flow Reserve Pullback
Authors: Juwon Kim, Seung Hun Lee, Joo Myung Lee, Doosup Shin, Ki Hong Choi, Ki-Hyun Jeon, Ho-Jun Jang, Hyun Kuk Kim, Sang Jin Ha, Taek Kyu Park, Jeong Hoon Yang, Young Bin Song, Joo-Yong Hahn, Joon-Hyung Doh, Eun-Seok Shin, Bon-Kwon Koo, Hyeon-Cheol Gwon
Journal: Journal of the American College of Cardiology (2021)
TCT-161 Functional Coronary Angiography–Derived Index of Microcirculatory Resistance and Microvascular Obstruction in Cardiac Magnetic Resonance Imaging After ST-Segment Elevation Myocardial Infarction
Authors: Doosup Shin, Juwon Kim, Ki Hong Choi, Seung Hun Lee, Hyun Sung Joh, Hyun Kuk Kim, Sung Mok Kim, Sang Jin Ha, MiJa Jang, Taek Kyu Park, Jeong Hoon Yang, Young Bin Song, Joo-Yong Hahn, Yeon Hyeon Choe, Hyeon-Cheol Gwon, Joo Myung Lee
Journal: Journal of the American College of Cardiology (2021)
TCT-348 Physiological and Angiographic Outcomes of PCI in Calcified Lesions After Rotational Atherectomy or Intravascular Lithotripsy
Authors: Emanuele Gallinoro, Giovanni Monizzi, Jeroen Sonck, Alessandro Candreva, Niya Mileva, Sakura Nagumo, Daniel Munhoz, Angelo Mastrangelo, Emanuele Barbato, Bernard De Bruyne, Carlos Collet
Journal: Journal of the American College of Cardiology (2021)
Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy
Authors: Jana Blazkova, Feng Gao, Manukumar Honnayakanahalli Marichannegowda, J. Shawn Justement, Victoria Shi, Emily J. Whitehead, Rachel F. Schneck, Erin D. Huiting, Kathleen Gittens, Mackenzie Cottrell, Erika Benko, Colin Kovacs, Justin Lack, Michael C. Sneller, Susan Moir, Anthony S. Fauci, Tae-Wook Chun
Journal: Nature Medicine (2021)
TCT-245 Safety and Feasibility of Epicardial Percutaneous Access and Maneuverability With a Novel Ablation Catheter for the Treatment of Atrial Fibrillation in a Porcine Model
Authors: Piotr Buszman, Karolina Łukasik, Stuart Deane, Marta Mazur, Marta Konopko, Carlos Fernandez, Michal Glanc, Paweł Kaźmierczak, Barry O’Brien, John Riley, Krzysztof Milewski, Pawel Buszman
Journal: Journal of the American College of Cardiology (2021)
TCT-262 Off-Hours Presentation and Clinical Outcomes in Patients Treated With Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: Analysis of the University of Ottawa Heart Institute STEMI Registry
Authors: Mohammed Rashid, George Wells, Aun-Yeong Chong, Alexander Dick, Michael Froeschl, Chris Glover, Benjamin Hibbert, Marino Labinaz, Juan Russo, Derek So, Jordan Bernick, Michel Le May
Journal: Journal of the American College of Cardiology (2021)
Possibility of Non-invasive Coronary Plaque Characterization with Dual Source Computed Tomography: Assessment Based on Optical Coherence Tomography Findings
Authors: Uemura Shiro, Soeda Tsunenari, Sugawara Yu, Ueda Tomoya, Okayama Satoshi, Watanabe Makoto, Saito Yoshihiko
Journal: Circulation (2013)
TCT-320 Pharmacokinetic and Pharmacodynamic Profile of PL-ASA, a Novel Phospholipid-Aspirin Complex Liquid Formulation, Compared to Enteric-Coated Aspirin at an 81-mg Dose – Results From a Prospective, Randomized, Crossover Study
Authors: Francesco Franchi, David Schneider, Jayne Prats, Weihong Fan, Fabiana Rollini, Lanonya Been, Heidi Taatjes-Sommer, Efthymios Deliargyris, Dominick Angiolillo
Journal: Journal of the American College of Cardiology (2021)
HLA associations, somatic loss of HLA expression, and clinical outcomes in immune aplastic anemia
Authors: Yoshitaka Zaimoku, Bhavisha A. Patel, Sharon D. Adams, Ruba Shalhoub, Emma M. Groarke, Audrey Ai Chin Lee, Sachiko Kajigaya, Xingmin Feng, Olga Julia Rios, Holly Eager, Lemlem Alemu, Diego Quinones Raffo, Colin O. Wu, Willy A. Flegel, Neal S. Young
Journal: Blood (2021)

Immune aplastic anemia (AA) features somatic loss of HLA class I allele expression on bone marrow cells, consistent with a mechanism of escape from T-cell-mediated destruction of hematopoietic stem and progenitor cells. The clinical significance of HLA abnormalities has not been well characterized. We examined the somatic loss of HLA class I alleles and correlated HLA loss and mutation-associated HLA genotypes with clinical presentation and outcomes after immunosuppressive therapy in 544 AA patients. HLA class I allele loss was detected in 92 (22%) of the 412 patients tested, in whom there were 393 somatic HLA gene mutations and 40 instances of loss of heterozygosity. Most frequently affected was HLA-B*14:02, followed by HLA-A*02:01, HLA-B*40:02, HLA-B*08:01, and HLA-B*07:02. HLA-B*14:02, HLA-B*40:02, and HLA-B*07:02 were also overrepresented in AA. High-risk clonal evolution was correlated with HLA loss, HLA-B*14:02 genotype, and older age, which yielded a valid prediction model. In 2 patients, we traced monosomy 7 clonal evolution from preexisting clones harboring somatic mutations in HLA-A*02:01 and HLA-B*40:02. Loss of HLA-B*40:02 correlated with higher blood counts. HLA-B*07:02 and HLA-B*40:01 genotypes and their loss correlated with late-onset of AA. Our results suggest the presence of specific immune mechanisms of molecular pathogenesis with clinical implications. HLA genotyping and screening for HLA loss may be of value in the management of immune AA. This study was registered at clinicaltrials.gov as NCT00001964, NCT00061360, NCT00195624, NCT00260689, NCT00944749, NCT01193283, and NCT01623167.
A large-scale outbreak of hand, foot and mouth disease, France, as at 28 September 2021
Authors: Audrey Mirand, Robert Cohen, Maxime Bisseux, Stéphanie Tomba, Fabienne Cahn Sellem, Nathalie Gelbert, Stéphane Béchet, Bruno Frandji, Christine Archimbaud, Amélie Brebion, Hélène Chabrolles, Christel Regagnon, Corinne Levy, Jean-Luc Bailly, Cécile Henquell
Journal: Eurosurveillance (2021)

We report a large-scale outbreak of hand, foot and mouth disease (HFMD) in France. As at 28 September 2021, 3,403 cases have been reported (47% higher than in 2018-19). We prospectively analysed 210 clinical samples; 190 (90.5%) were enterovirus-positive. Most children presented with atypical HFMD. Coxsackievirus (CV)A6 (49.5%; 94/190) was predominant; no enterovirus A71 was detected. Dermatological and neurological complications of HFMD justify prospective syndromic and virological surveillance for early detection of HFMD outbreaks and identification of associated types.
Inequalities in developing multimorbidity over time: A population-based cohort study from an urban, multi-ethnic borough in the United Kingdom
Authors: Alessandra Bisquera, Ellie Bragan Turner, Lesedi Ledwaba-Chapman, Rupert Dunbar-Rees, Nasrin Hafezparast, Martin Gulliford, Stevo Durbaba, Marina Soley-Bori, Julia Fox-Rushby, Hiten Dodhia, Mark Ashworth, Yanzhong Wang
Journal: The Lancet Regional Health - Europe (2021)

Social and material deprivation accelerate the development of multimorbidity, yet the mechanisms which drive multimorbidity pathways and trajectories remain unclear. We aimed to examine the association between health inequality, risk factors and accumulation or resolution of LTCs, taking disease sequences into consideration.We conducted a retrospective cohort of adults aged 18 years and over, registered between April 2005 and May 2020 in general practices in one inner London borough (n = 826,936). Thirty-two long term conditions (LTCs) were selected using a consensus process, based on a definition adapted to the demographic characteristics of the local population. sThe development and resolution of these LTCs were examined according to sociodemographic and clinical risk factors (hypertension; moderate obesity (BMI 30·0-39·9 kg/m2), high cholesterol (total cholesterol > 5 mmol/L), smoking, high alcohol consumption (>14 units per week), and psychoactive substance use), through the application of multistate Markov chain models.Participants were followed up for a median of 4.2 years (IQR = 1·8 - 8·4); 631,760 (76%) entered the study with no LTCs, 121,424 (15%) with 1 LTC, 41,720 (5%) with 2 LTCs, and 31,966 (4%) with three or more LTCs. At the end of follow-up, 194,777 (24%) gained one or more LTCs, while 45,017 (5%) had resolved LTCs and 27,021 (3%) died. In multistate models, deprivation (hazard ratio [HR] between 1·30 to 1·64), female sex (HR 1·13 to 1·20), and Black ethnicity (HR 1·20 to 1·30; vs White) were independently associated with increased risk of transition from one to two LTCs, and shorter time spent in a healthy state. Substance use was the strongest risk factor for multimorbidity with an 85% probability of gaining LTCs over the next year. First order Markov chains identified consistent disease sequences including: chronic pain or osteoarthritis followed by anxiety and depression; alcohol and substance dependency followed by HIV, viral hepatitis, and liver disease; and morbid obesity followed by diabetes, hypertension, and chronic pain.We examined the relations among 32 LTCs, taking the order of disease occurrence into consideration. Distinctive patterns for the development and accumulation of multimorbidity have emerged, with increased risk of transitioning from no conditions to multimorbidity and mortality related to ethnicity, deprivation and gender. Musculoskeletal disorders, morbid obesity and substance abuse represent common entry points to multimorbidity trajectories.
Targeted adjuvant therapy in non-small cell lung cancer: trick or treat?
Authors: Lizza E.L. Hendriks, Jan van Meerbeeck, Jacques Cadranel
Journal: European Respiratory Journal (2021)

<b>Immuno- and targeted therapy improved survival in metastatic NSCLC, but before their implementation in early disease, several challenges need to be overcome. Adequate staging is important, and molecular testing must be incorporated in early disease.</b>https://bit.ly/3heLe6W
“Pincer movement”: Reversing cisplatin resistance based on simultaneous glutathione depletion and glutathione S-transferases inhibition by redox-responsive degradable organosilica hybrid nanoparticles
Authors: Boyi Niu, Yixian Zhou, Kaixin Liao, Ting Wen, Sixian Lao, Guilan Quan, Xin Pan, Chuanbin Wu
Journal: Acta Pharmaceutica Sinica B (2021)

The therapeutic efficacy of cisplatin has been restricted by drug resistance of cancers. Intracellular glutathione (GSH) detoxification of cisplatin under the catalysis of glutathione S-transferases (GST) plays important roles in the development of cisplatin resistance. Herein, a strategy of "pincer movement" based on simultaneous GSH depletion and GST inhibition is proposed to enhance cisplatin-based chemotherapy. Specifically, a redox-responsive nanomedicine based on disulfide-bridged degradable organosilica hybrid nanoparticles is developed and loaded with cisplatin and ethacrynic acid (EA), a GST inhibitor. Responding to high level of intracellular GSH, the hybrid nanoparticles can be gradually degraded due to the break of disulfide bonds, which further promotes drug release. Meanwhile, the disulfide-mediated GSH depletion and EA-induced GST inhibition cooperatively prevent cellular detoxification of cisplatin and reverse drug resistance. Moreover, the nanomedicine is integrated into microneedles for intralesional drug delivery against cisplatin-resistant melanoma. The in vivo results show that the nanomedicine-loaded microneedles can achieve significant GSH depletion, GST inhibition, and consequent tumor growth suppression. Overall, this research provides a promising strategy for the construction of new-type nanomedicines to overcome cisplatin resistance, which extends the biomedical application of organosilica hybrid nanomaterials and enables more efficient chemotherapy against drug-resistant cancers.